SCHEDULE 13G: Endeavour Medtech Funds Disclose 5.2% Stake in Kestra Medical Technologies

Endeavour Medtech Growth II LP, Endeavour Medtech Growth II Parallel LP, and Endeavour Medtech II GP Limited have collectively reported a beneficial ownership of 5.2% in Kestra Medical Technologies, Ltd.'s common shares.

Summary

• Endeavour Medtech Growth II LP, Endeavour Medtech Growth II Parallel LP, and Endeavour Medtech II GP Limited (collectively, the "Reporting Persons") have filed a Schedule 13G indicating their beneficial ownership in Kestra Medical Technologies, Ltd.
• The Reporting Persons collectively beneficially own 2,646,899 common shares of Kestra Medical Technologies, Ltd.
• This aggregate ownership represents 5.2% of Kestra Medical Technologies, Ltd.'s common shares outstanding.
• The percentage is calculated based on 51,348,656 common shares outstanding as of April 17, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q.
• The shares are held both directly and indirectly through West Affum Holdings, L.P., with 972,077 shares held directly by Endeavour Medtech Growth II LP and 1,628,023 shares indirectly held through West Affum Holdings, L.P. for Endeavour Medtech Growth II LP.
• Additionally, 17,497 shares are held directly by Endeavour Medtech Growth II Parallel LP and 29,302 shares are indirectly held through West Affum Holdings, L.P. for Endeavour Medtech Growth II Parallel LP.
• The Reporting Persons have shared voting power over all 2,646,899 shares and shared dispositive power over 989,574 shares.
• Endeavour Medtech II GP Limited serves as the general partner for both Endeavour Medtech Growth II LP and Endeavour Medtech Growth II Parallel LP.
• The Reporting Persons disclaim beneficial ownership of common shares held by West Affum Holdings, L.P. on behalf of third-party holders.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of a significant ownership stake by an institutional investor, which is generally viewed as a positive signal of confidence in the company, though it does not contain performance metrics.

Positives

• The disclosure of a significant stake (5.2%) by institutional investors like Endeavour Medtech can signal confidence in Kestra Medical Technologies' future prospects.
• The investment by a specialized 'Medtech Growth' fund suggests a strategic alignment with Kestra Medical Technologies' industry focus.

Future Outlook

The document mentions a 'Post-IPO Distribution' where Endeavour Medtech Growth II LP and Endeavour Medtech Growth II Parallel LP are entitled to receive additional common shares from West Affum Holdings, L.P. approximately nine months after Kestra Medical Technologies' initial public offering. The actual number of shares will be determined at the time of distribution based on the liquidation value of West Affum Holdings, L.P.

Industry Context

This filing indicates a significant investment by Endeavour Medtech, a fund focused on the medical technology sector, into Kestra Medical Technologies, reinforcing the ongoing investor interest and capital allocation within the medtech industry.

Related Party Transactions

• Endeavour Medtech Growth II LP and Endeavour Medtech Growth II Parallel LP indirectly hold a portion of their shares through West Affum Holdings, L.P., from which they are entitled to receive shares via a Post-IPO Distribution.
• Endeavour Medtech II GP Limited is the general partner of Endeavour Medtech Growth II LP and Endeavour Medtech Growth II Parallel LP, forming a 'group' for reporting purposes.

Stakeholder Impact

• Shareholders may view the significant stake taken by Endeavour Medtech as a positive indicator of institutional confidence in Kestra Medical Technologies.
• The disclosure provides transparency regarding a major investor's position in the company.

Next Steps

• The Post-IPO Distribution of Common Shares from West Affum Holdings, L.P. to Endeavour Medtech Growth II LP and Endeavour Medtech Growth II Parallel LP is expected to occur approximately nine months after the consummation of Kestra Medical Technologies' initial public offering.

Key Dates

Keywords

Kestra Medical Technologies, Endeavour Medtech, Schedule 13G, beneficial ownership, medical technology, institutional investment, common shares, equity stake